Psychedelic-Assisted Psychotherapy: Therapeutic Relationship, Suggestibility, and Set and Setting

Share

Narrative Clinical Review. This page provides the verified citation, abstract, and full-text PDF for the journal article.

Clinical boundary: The reviewed interventions are compound-specific, highly supported treatment packages studied in selected populations; they do not justify unsupervised use or a general class claim. Medical and psychiatric screening, enhanced consent, explicit boundaries, legal and professional governance, and adverse-event monitoring are essential.

Publication Details

  • Author: Christian Jonathan Haverkampf
  • Journal: The Journal of Psychiatry Psychotherapy and Communication
  • Publication date: 2022-12-31
  • Volume, issue, pages: 11(4), 111–120
  • Article type: Narrative Clinical Review

Recommended citation: Haverkampf, C. J. (2022). Psychedelic-Assisted Psychotherapy: Therapeutic Relationship, Suggestibility, and Set and Setting. The Journal of Psychiatry Psychotherapy and Communication, 11(4), 111–120.

Abstract

Psychedelic-assisted psychotherapy is not a single treatment. It joins a psychoactive compound, a selected participant, preparatory and follow-up encounters, an interpersonal relationship, and a deliberately arranged setting. This narrative clinical review examines evidence available through 30 November 2022, with particular attention to therapeutic alliance, suggestibility, expectancy, consent, and set and setting. Early controlled trials of psilocybin- and 3,4-methylenedioxymethamphetamine-assisted interventions reported clinically important signals in several narrowly defined populations. They did not establish a transferable class effect, the independent contribution of psychotherapy, or effectiveness in routine practice. Functional unblinding, high expectancy, small selected samples, intensive support, and uncertain durability limit inference. The same conditions that may facilitate emotional learning also intensify power. During an altered state, a therapist's language, touch, metaphysical assumptions, and responses to apparent memory can shape meaning when the patient's capacity to evaluate influence is changed. Ethical practice therefore requires enhanced consent before exposure, compound-specific medical and psychiatric screening, explicit boundaries, culturally responsive preparation, non-directive support, adverse-event monitoring, and integration that neither certifies revelation nor dismisses it. The therapeutic relationship should be studied as a possible active ingredient and a possible source of harm. Until comparative process research matures, clinicians should distinguish evidence from interpretation, protect uncertainty, and avoid presenting an investigational package as a pharmacological shortcut or a universally transformative psychotherapy.

Keywords

psychedelic-assisted psychotherapy; psilocybin; MDMA; therapeutic alliance; suggestibility; set and setting; informed consent; integration

Full Text

Open the full-text PDF

The PDF is searchable and preserves the journal layout and pagination used in the citation.

Related Information

Health Information and Safety

This journal article is educational and research-oriented. It is not a personal diagnosis, treatment plan, medication instruction, crisis service, or substitute for assessment by a suitably qualified clinician who knows the person’s circumstances.

Do not start, stop, or change medication or another treatment solely because of information on this page. New, severe, persistent, or worsening symptoms, or uncertainty about risk, require individual professional assessment.

If there is immediate danger or a risk of harm, contact local emergency services or urgent support. In Ireland, see:

Website copy first made available on 28 August 2026. The journal citation retains the article’s issue date.

Share